Medicine & Life Sciences

1. Breast Neoplasms 100%
2. Tamoxifen 37%
3. Neoplasms 37%
4. Melanoma 37%
5. Aromatase Inhibitors 27%
6. Survival 25%
7. Drug Therapy 25%
8. Trastuzumab 22%
9. Therapeutics 22%
10. Estrogen Receptors 21%
11. Recurrence 21%
12. Letrozole 18%
13. Progression-Free Survival 17%
14. Cytochrome P-450 CYP2D6 16%
15. Anastrozole 15%
16. Neoadjuvant Therapy 14%
17. Carboplatin 14%
18. Paclitaxel 14%
19. pazopanib 13%
20. Triple Negative Breast Neoplasms 13%
21. Aromatase 11%
22. Breast 11%
23. Cyclophosphamide 11%
24. Doxorubicin 10%
25. Breast Density 10%
26. Confidence Intervals 10%
27. Disease-Free Survival 10%
28. Radiotherapy 10%
29. 4-hydroxy-N-desmethyltamoxifen 10%
30. Fulvestrant 9%
31. Polyurethanes 9%
32. Carcinoma 9%
33. exemestane 8%
34. Heterografts 8%
35. Neoplasm Metastasis 8%
36. Multiple Myeloma 8%
37. Adjuvant Chemotherapy 8%
38. Biopsy 7%
39. Estrogens 7%
40. Clinical Trials 7%
41. Serum 7%
42. Sentinel Lymph Node 7%
43. 130-nm albumin-bound paclitaxel 7%
44. Lymph Node Excision 7%
45. Lead 7%
46. Anaplastic Thyroid Carcinoma 6%
47. human ERBB2 protein 6%
48. Tumor Biomarkers 6%
49. Meningioma 6%
50. Endometrial Neoplasms 6%